National Instruments Recognizes Sanarus' Innovative Visica 2(TM) System
The Visica System is a minimally invasive cryotechnology device clearedfor market by the Food and Drug Administration (FDA) for the treatment offibroadenomas, a common benign breast condition found in at least 10 percentof all women in the United States. The procedure uses cryoablation, or extremecold, to destroy tumors without requiring stitches or general anesthesia. Theoffice-based procedure, which usually takes less than 30 minutes, involvesplacing a small needle into the center of the tumor using ultrasound guidance.The System creates very cold temperatures at the needle tip, freezing thefibroadenoma, damaging the tumor cells and causing them to break down toprevent re-growth.
Previously, surgical removal typically involved general anesthesia, a dayin the hospital, an incision requiring stitches and several days of recovery.Cosmetic outcomes following surgical removal of a fibroadenoma can betroubling to patients. Because cryoablation does not involve the removal oftissue and can be performed using a small incision that does not requirestitches, cosmetic outcomes are excellent.
Visica 2 provides women with a treatment option for their fibroadenomasthat safely and effectively treats the lump in their breast. Even thoughbenign, fibroadenomas can cause pain, discomfort and a great deal of anxiety.Prior to Visica 2 many women chose to live with the pain and anxiety of a lumpin their breast because their only option was surgery. Now they have a simplein-office treatment that relives the pain and anxiety and treats theirfibroadenoma without negative effects to the shape or size of their breast.
"We're very pleased that NI has recognized our success in developing amedical device used to treat breast tumors in a less invasive and nearlypainless procedure while maintaining the design process within strictregulatory guidelines," said John F. Howe, president and Chief ExecutiveOfficer of Sanarus. "Receiving industry recognition of this caliber is a nicecomplement to the positive feedback we've been getting from physicians andtheir patients who have undergone treatment with the Visica System.Nationwide, there has been no reported fibroadenoma re-growth in more than2,000 procedures."
More than 110 authors from 13 countries submitted papers for the GraphicalSystem Design Achievement Awards. A judging committee of more than 30technical publication editors and NI experts judged papers submitted across 10application categories. In addition to the Humantarian category, the categoryfinalists were considered for the Editors Choice, Green Engineering and theOverall Application of the Year awards. The Visica 2(TM) Treatment System alsowas named a finalist in the Overall Application of the Year category.
"Thanks to NI, we quickly and efficiently developed an embedded controlsystem with a user-friendly GUI for the Visica 2 System while maintaining thehighest quality, and ultimately, ensuring the safety of our customers'patients," said Randy Sullivan, Chief Operating Officer, Sanarus. "NI played afundamental part in achieving our goals under extreme time-to-market pressureto deliver a device that would dramatically reduce the emotional and physicaldiscomfort of patients undergoing tumor treatment. Our product design,prototype, and eventual deployment timelines were met because of the graphicalsystem design platform from NI."
The award was presented to Sanarus by National Instruments President, CEOand Co-founder Dr. James Truchard, Co-founder and Business and TechnologyFellow Jeff Kodosky and International Marketing Director Dave Wilson.
To learn more about the
You May Also Like